• Home
  • Our Mission
  • Our Science
  • Team
  • Careers
  • News & Publications
  • Contact
Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting

Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting

by dividef | May 17, 2022 | Press Release

Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting Read...
Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board

Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board

by dividef | May 10, 2022 | Press Release

Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board Read...
Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis

Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis

by dividef | May 5, 2022 | Press Release

Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis Read...

Recent Posts

  • Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis
  • Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting
  • Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board
  • Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis

Recent Comments

    Archives

    • February 2023
    • May 2022

    Categories

    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact | Privacy Policy

    ©2022. Genascence. All Rights Reserved. Site by GOODLAB